Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q4 2015 (← Previous) (Next →)

Filing Date: Feb 10, 2016

Total Value ($000): $179,685 (100.0% shares, 0.0% debt)

Holdings (10)

— Juno Therapeutics 30.1%

Value ($000) $54,062 Shares 1,229,512 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 22.6%

Value ($000) $40,574 Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Egalet 17.3%

Value ($000) $31,021 Shares 2,814,928 Est. Cost $6.01 Unrealized —

— FibroGen 13.9%

Value ($000) $25,052 Shares 822,175 Est. Cost $27.34 Unrealized —

— Nabriva Therapeutics 6.1%

Value ($000) $11,023 Shares 1,145,890 Est. Cost $9.50 Unrealized —

— Pieris Pharmaceuticals 3.2%

Value ($000) $5,688 Shares 2,483,949 Est. Cost $1.83 Unrealized —

— ESSA Pharma 2.6%

Value ($000) $4,636 Shares 1,090,909 Est. Cost $6.31 Unrealized —

— Proteon Therapeutics 2.2%

Value ($000) $3,878 Shares 250,000 Est. Cost $10.40 Unrealized —

— Dicerna Pharmaceuticals 1.5%

Value ($000) $2,652 Shares 223,457 Est. Cost $16.47 Unrealized —

— CymaBay Therapeutics 0.6%

Value ($000) $1,099 Shares 650,000 Est. Cost $1.94 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,229,512	$54,062	30.1%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,138,872	$40,574	22.6%	$38.55	—	Common Stock	699374302
—	Egalet	2,814,928	$31,021	17.3%	$6.01	—	Common Stock	28226B104
—	FibroGen	822,175	$25,052	13.9%	$27.34	—	Common Stock	31572Q808
—	Nabriva Therapeutics	1,145,890	$11,023	6.1%	$9.50	—	Sponsored ADR	62957M104
—	Pieris Pharmaceuticals	2,483,949	$5,688	3.2%	$1.83	—	Common Stock	720795103
—	ESSA Pharma	1,090,909	$4,636	2.6%	$6.31	—	Common Stock	29668H104
—	Proteon Therapeutics	250,000	$3,878	2.2%	$10.40	—	Common Stock	74371L109
—	Dicerna Pharmaceuticals	223,457	$2,652	1.5%	$16.47	—	Common Stock	253031108
—	CymaBay Therapeutics	650,000	$1,099	0.6%	$1.94	—	Common Stock	23257D103